Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
An Auto-injector is basically a medical tool of pen shaped designed to deliver a dose of a particular drug to the patient. The drug is delivered by inserting the syringe needle at a desired site of injection, and on push of button. These auto injectors are easy to use and are intended for self-administration by patients, without relying on trained personnel. Auto-injector is significantly used for various mild and severe allergic reactions. If allergic reaction are not cured, then it can even lead to life-threatening condition such as anaphylaxis. Further, the treatment of diseases like multiple sclerosis and rheumatoid arthritis is being performed with the auto injector device. The injecting site of that particular drug is dependent on the nature of the drug, but it is normally taken through the intramuscular route.
The auto injector market is mainly driven by the factors such as increase in anaphylactic incidences, rising awareness among patients, and patient’s preference to choose self-administration of injections. Further, increased level of the usage of the device in case of severe pain and government’s support for allowing the marketing of the instrument in various locations will further boost the growth of the market. In addition, advancement of auto-injector devices to provide more access to the patients is expected to drive growth of the market. However, the high cost of these devices and its substitute product including oral tablets and injections can act as a restraint for the market growth.
Increasing prevalence and incidences of anaphylaxis and food allergies around the world is majorly responsible for the growth of the global auto-injectors market. The World Allergy Organisation (WAO) estimate of allergy prevalence of the whole population by country ranges between 10 - 40%. Allergy is a very common ailment, affecting more than 20% of the populations of most developed countries. It is most common chronic disease in Europe. More than 150 million Europeans suffer from chronic allergic diseases and the current prediction is that by 2025 half of the entire EU population will be affected. This in turn, promotes the growth of the auto-injector market.
.jpg)
The global auto-injector market is segmented on the basis of type, application, end user and geography.
Based on type, the market has been bifurcated into disposable auto- injectors and reusable auto injectors. The disposable auto- injector comes in pre-filled medicine, and these are inexpensive compared to reusable auto-injector. However, it can be more expensive if used regularly. The reusable pen can be recharged for frequent use, and cartridge can be interchangeable offering more strain options. These cartridges are preferred choice for long term use, as reusable auto injector are more expensive out of gate but less expensive over the long term.
Auto injector market by application is classified into Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Anaphylaxis and Other Therapies (Cardiovascular Diseases, Migraines, Psoriasis, and Anemia). Anaphylaxis is a potentially life-threatening systemic allergic reaction. Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease that affects connective tissues. It causes joints to swell and can result in pain, stiffness, and progressive loss of function. According to the CDC, From 2013–2015, an estimated 54.4 million US adults (22.7%) annually had some form of arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia. And, by 2040, an estimated 78 million (26%) US adults aged 18 years or older are projected to have doctor-diagnosed arthritis. Thus, the demand for auto-injectors for this therapy segment is fuelled by the increasing incidence of RA across the world.
Auto-injector market by end user is segmented into home care settings and hospitals & clinics. The increase in self-administration of medication at home, more convenience, rising incidences of Rheumatoid Arthritis rapid growth in the geriatric population across the globe, are the factors leading to the significant market share of the home care segment.
On the basis of regional presence, global auto-injectors market is segmented into North America, Europe, Asia Pacific, and Rest of the World (ROW).
North America is anticipated to lead the global auto-injectors market in terms of revenue attributed to factors such as to the advanced healthcare infrastructure, advancements in medical devices technologies, higher demand for quality products, and favourable reimbursement policies.
Asia Pacific market is anticipated to grow at the fastest growth rate during the forecast period, due to increasing anaphylaxis and food allergies in this region. Further, rising medical tourism and high growth of the medical devices industry in Asia pacific, is anticipated to drive the growth of the global auto-injectors market during the forecast period.
The major players in auto-injector market includes AbbVie Inc., Teva Pharmaceuticals, Antares Pharma Inc., Biogen Idec, Inc., Becton, Dickinson and Company, Mylan, Inc., Pfizer, Inc., Novartis International AG, Unilife Corporation, Ypsomed Holdings AG, Scandinavian Health Limited (SHL) Group, ELI Lilly , Amgen , Consort Medical and Sanofi S. A among others. Besides, the auto-injectors market is anticipated to witness the emergence of many other local participants over the forecast predicted period.
The global auto-injector market is segmented on the basis of type, application, end user and geography.
On the basis of type, the market has been categorised into disposable auto- injectors and reusable auto injectors. The disposable auto- injector comes pre filled medicine, and these are inexpensive compared to reusable auto-injector. Auto-injector market by end user is bifurcated into home care settings and hospitals & clinics.
There are several application of these devices for the treatment of diseases that include rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis and other therapies (cardiovascular diseases, migraines, psoriasis, and anemia). The demand for auto-injectors for rheumatoid arthritis segment is fuelled by the rising incidence of this disease across the globe.
Geographically, the market is analysed across regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The market is expected to be growing at fastest CAGR in APAC region during forecast period owing to rising anaphylaxis and food allergies and rising medical tourism in this region.
Why to buy this report:
